US20190282583A1 – September 19, 2019 – COMPOSITIONS AND METHODS FOR THE TREATMENT OF SUBSTANCE USE DISORDERS, ADDICTION, AND PSYCHIATRIC DISORDERS

Please complete the required fields.




Inventors :

Michael Detke; Martin Phillips; Robert Linke

Owner :

EMBERA NEUROTHERAPEUTICS, INC.

Application Number :

US16433543

Document Number :

US20190282583A1

Priority Date :

June 6, 2019

Filing Date :

June 6, 2019

Date of Grant/ Publication :

September 19, 2019

Class :

A61K31 / 53; A61P25 / 30; A61K31 / 519; A61K31 / 506; A61K31 / 4196; A61K45 / 06; A61K31 / 4168; A61K31 / 343; A61K31 / 138; A61K31 / 496; A61K31 / 4188

Abstract

The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the HPA axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, coedine, hydrocodone, nicotine, alcohol, prescription medication (e.g., Percodan®, Percoset®), marijuana, tobacco, methadone, food), addiction to an activity (e.g., gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, ADHD, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (e.g., Prader Willi Syndrome), obesity, depression, menopause, prementsrual syndrome (PMS), obsessive compulsive disorder (OCD), social anxiety, generalized anxiety disorder, dysthymia, or schizophrenia.

Claim(s)

27 . A method of treating a disorder selected from an addiction to a substance, addiction to an activity, substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, ADHD, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders, obesity, depression, menopause, prementsrual syndrome (PMS), obsessive compulsive disorder (OCD), social anxiety, generalized anxiety disorder, dysthymia, and schizophrenia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a first agent selected from a CRF-1 antagonist and a cortisol inhibitor; and a second agent selected from a selective serotonin reuptake inhibitor (SSRI), a beta blocker, an antipsychotic, an azapirone, and an alpha-adrenergic agonist.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login